PEOPLE - Changes at Andaris (UK):
This article was originally published in Clinica
Executive Summary
Andaris, a UK developer of in vivo imaging and therapeutic products, has appointed Dr Stuart Collinson of Glaxo Wellcome CEO. David Heath, Andaris' lead founder, has retired as chairman but remains a non-executive director and consultant to the UK company. Gordon Hall, previously managing director of Shield Diagnostics, joins as non-executive chairman.
You may also be interested in...
Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Moderna Ready To File Vaccine After Second Impressive Read-Out
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: